Total Antibody to Infliximab ELISA

Enzyme immunoassay for the semi-quantitative determination of total (free and drug-bound) antibodies to Infliximab (Remicade®, Remsima®) in serum and plasma.

Due to the specific assay design this test measures the antibodies against Infliximab even in a high excess of the drug (up to 20-fold). Results are expressed in tAU (total arbitrary units).

Reference: IG-TA101

Barcode: 8699316552482

Legal Status: CE-Mark

Intended Use: This kit has been developed for the detection of total level of anti-drug antibodies in research and diagnostic uses. It is suitable for Therapeutical Drug Monitoring (TDM) purposes.

Assay Design:

Related Documents


Quality Control Certificates

Remicade® is a trademark of Janssen Biotech, Inc./Merck & Co.

Remsima® is a trademark of CellTrion Inc.

The Kit at a glance:

ig-ta-101

Required Volume (µL) 20
Incubation Time (min) 75
Sample Serum or Plasma
Package Size 96 Tests
Results in Total Arbitrary Units (tAU/mL)
Cut-Off (tAU/mL) 10
Detection Limit (tAU/mL) 10
Shelf Life (years) 1